E7820
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Trial Timeline
Aug 13, 2021 → Jun 19, 2025
NCT ID
NCT05024994About E7820
E7820 is a phase 2 stage product being developed by Eisai for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05024994. Target conditions include Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05024994 | Phase 2 | Completed |
| NCT00078637 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia